In addition, SLC31A1 transports platinum drugs across the plasma membrane, and in patients with non-small cell lung cancer, SLC31A1 is a potential pharmacogenetic biomarker for clinical outcomes [15, 16]. This evidence concerns the gene SLC31A1 and non-small cell lung carcinoma.